Jim Cramer Says “Danaher’s Been Acting Much Better”

Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer recently discussed. Cramer noted that he still likes the stock for the Charitable Trust, as he said:

“Now, first, there’s tried and true, but lately trying Danaher, DHR, a conglomerate that became more focused on life sciences diagnostics when it spun off its water and product quality testing business as Veralto a couple years ago. We own Danaher for the Charitable Trust. I gotta tell you, it’s been really frustrating for the past couple years, even though we bought it during the post-COVID washout. Turns out that was early, as the stock languished for a very long time. Lately, though, Danaher’s been acting much better. It’s up 31% from its April low. It’s up 25% from its more recent low… in September. Now get this, in late October, in the middle of the stock’s most recent rally, Danaher reported a strong quarter driven by solid growth numbers from the company’s crucial bioprocessing division, which had been so languishing. They posted a small revenue beat with a solid 3% organic growth, as well as a large earnings beat. While management merely reiterated their full-year sales and earnings forecast, that was enough to get the stock, I told you it’s been… in just a hell hole, get the stock moving higher. Looking ahead, Wall Street expects Danaher to put up its best growth in years in 2026, mid-single-digit revenue growth, and high single-digit earnings growth. If they can hit those targets, I bet the stock keeps running. I still like the stock for the Charitable Trust, but we bought some stock real low in this one, and I’m thinking of trimming it if the stock jumps another 10 points, but 10 could be a lot.”

A stock market graph. Photo by Alesia Kozik on Pexels

Danaher Corporation (NYSE:DHR) provides instruments, consumables, software, and services used in bioprocessing, life sciences research, and clinical diagnostics.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.